The influence of CYP2C9 gene polymorphisms on the efficacy of losartan in patients with grade I-II arterial hypertension
- Authors: Sinitsina I.I1, Boyarko A.V2, Temirbulatov I.I1, Mirzaev K.B1, Grishina E.A1, Sozaeva Z.A1, Akmalova K.A1, Shuev G.N1, Denisenko N.P1, Kachanova A.A1, Sychev D.A1
-
Affiliations:
- Russian Medical Academy of Continuous Professional Education
- LMS Clinic
- Issue: Vol 28, No 3 (2021)
- Pages: 57-61
- Section: Articles
- URL: https://journals.eco-vector.com/2073-4034/article/view/313104
- DOI: https://doi.org/10.18565/pharmateca.2021.3.57-61
- ID: 313104
Cite item
Abstract
Keywords
Full Text
![Restricted Access](https://journals.eco-vector.com/lib/pkp/templates/images/icons/text_lock.png)
About the authors
I. I Sinitsina
Russian Medical Academy of Continuous Professional EducationMoscow, Russia
A. V Boyarko
LMS ClinicMoscow, Russia
Ilyas I Temirbulatov
Russian Medical Academy of Continuous Professional Education
Email: temirbulatov.ilyas@gmail.com
Resident at the Department of Clinical Pharmacology and Therapy Moscow, Russia
K. B Mirzaev
Russian Medical Academy of Continuous Professional EducationMoscow, Russia
E. A Grishina
Russian Medical Academy of Continuous Professional EducationMoscow, Russia
Zh. A Sozaeva
Russian Medical Academy of Continuous Professional EducationMoscow, Russia
K. A Akmalova
Russian Medical Academy of Continuous Professional EducationMoscow, Russia
G. N Shuev
Russian Medical Academy of Continuous Professional EducationMoscow, Russia
N. P Denisenko
Russian Medical Academy of Continuous Professional EducationMoscow, Russia
A. A Kachanova
Russian Medical Academy of Continuous Professional EducationMoscow, Russia
D. A Sychev
Russian Medical Academy of Continuous Professional EducationMoscow, Russia
References
- Turner S.T., Schwartz G.L., Chapman A.B., et al. Antihypertensive pharmacogenetics: Getting the right drug into the right patient. J Hypertens. 2001;19:1-11.
- Williams B., Mancia G., Spiering W., et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension. Eur. Heart J. 2018;39:3021-104. doi: 10.1093/eurheartj/ehy339.
- Suchard M.A., Schuemie M.J., Krumholz H.M., et al. Comprehensive comparative effectiveness and safety of first-line antihypertensive drug classes: a systematic, multinational, large-scale analysis. Lancet. 2019;394:1816-26. doi: 10.1016/S0140-6736(19)32317-7.
- Sica D.A., Gehr T.W.B., Ghosh S. Clinical pharmacokinetics of losartan. Clin Pharmacokinet. 2005;44:797-814. doi: 10.2165/00003088-200544080-00003.
- Spiering W., Kroon A.A., Fuss-Lejeune M.J.M.J., De Leeuw PW. Genetic contribution to the acute effects of angiotensin II type 1 receptor blockade. J. Hypertens. 2005;23:753-58. doi: 10.1097/01. hjh.0000163143.66965.06.
- Yasar U., Tybring G., Hidestrand M., et al. Role of Cyp2C9 Polymorphism in Losartan Oxidation. Drug Metab Dispos.2001;29:1051-56.
- Wang B., Wang J., Huang S.-Q., et al. Genetic Polymorphism of the Human Cytochrome P450 2C9 Gene and Its Clinical Significance. Curr Drug Metab. 2009;10:781-834. doi: 10.2174/138920009789895480.
- Yasar U., Forslund-Bergengren C., Tybring G., et al. Pharmacokinetics of losartan and its metabolite E-3174 in relation to the CYP2C9 genotype. Clin Pharmacol Ther. 2002;71:89-98. doi: 10.1067/mcp.2002.121216.
- Zhou Y., Ingelman-Sundberg M., Lauschke V.M. Worldwide Distribution of Cytochrome P450 Alleles: A Meta-analysis of Population-scale Sequencing Projects. Clin Pharmacol Ther. 2017;102:688-700. doi: 10.1002/cpt.690.
- Мирзаев К.Б., Федоринов Д.С., Иващенко Д.В., Сычев Д.А. Мультиэтнический анализ кардиологических фармакогенетических маркеров генов цитохрома Р450 и мембранных транспортеров в российской популяции. Рациональная фармакотерапия в кардиологии. 2019;15(3):393-406
- Cabaleiro T., Roman M., Ochoa D., et al. Evaluation of the relationship between sex, polymorphisms in CYP2C8 and CYP2C9, and pharmacokinetics of angiotensin receptor blockers. Drug Metab. Dispos. 2013;41:22429. doi: 10.1124/dmd.112.046292
- Yasar Ü., Dahl M.L., Christensen M., Eliasson E. Intraindividual variability in urinary losartan oxidation ratio, an in vivo marker of CYP2C9 activity. Br. J. Clin. Pharmacol. 2002;54:183-85.
- Sekino K., Kubota T., Okada Y., et al. Effect of the single CYP2C9*3 allele on pharmacokinetics and pharmacodynamics of losartan in healthy Japanese subjects. Eur J Clin Pharmacol 2003;59:589-92. doi: 10.1007/s00228-003-0664-5.
- Joy M.S., Dornbrook-Lavender K., Blaisdell J., et al. CYP2C9 genotype and pharmacodynamic responses to losartan in patients with primary and secondary kidney diseases. Eur. J. Clin. Pharmacol. 200965:947-53. doi: 10.1007/s00228-009-0707-7.
- de Andres F., Teran S., Bovera M., et al. Multiplex Phenotyping for Systems Medicine: A One-Point Optimized Practical Sampling Strategy for Simultaneous Estimation of CYP1A2, CYP2C9, CYP2C19, and CYP2D6 Activities Using a Cocktail Approach. OMICS. 2016;20:88-96. Doi: 10.1089/ omi.2015.0131.
- Сычев Д.А. Рекомендации для фармацевтических компаний по изучению биотрансформации и транспортеров новых лекарственных средств: дизайн исследований, анализ данных и внесение информации в инструкции по применению. Науч. ред. В.Г. Кукес. М., 2009
- Parati G., Stergiou G., O'Brien E., et al. European Society of Hypertension practice guidelines for ambulatory blood pressure monitoring. J Hypertens. 2014;32:1359-66. doi: 10.1097/HJH.0000000000000221.
- Gaborieau V., Delarche N., Gosse P Ambulatory blood pressure monitoring versus self-measurement of blood pressure at home: Correlation with target organ damage. J. Hypertens. 2008;26:1919-27. doi: 10.1097/HJH.0b013e32830c4368.
- Clement D.L., De Buyzere M.L., De Bacquer D.A., et al. Prognostic Value of Ambulatory Blood-Pressure Recordings in Patients with Treated Hypertension. N Engl J Med. 2003;348:2407-15. Doi: 10.1056/ nejmoa022273.
- Banegas J.R., Ruilope L.M., de la Sierra A., et al. Relationship between Clinic and Ambulatory Blood-Pressure Measurements and Mortality. N Engl J Med. 2018;378:1509-20. doi: 10.1056/nejmoa1712231.
- Sega R., Facchetti R., Bombelli M., et al. Prognostic value of ambulatory and home blood pressures compared with office blood pressure in the general population: Follow-up results from the Pressioni Arteriose Monitorate e Loro Associazioni (PAMELA) study. Circulation. 2005;111:1777-83. doi: 10.1161/01. CIR.0000160923.04524.5B.
Supplementary files
![](/img/style/loading.gif)